Access Menu

Log in via Social

Log in with LinkedIn
Geneaire, Inc.

Geneaire, Inc.

Bringing the first proven Alzheimer’s inhibitor to market after 30 years of Genomics research and clinical trials.

Verify Investor Status to make a reservation

Deal Type

Equity

Funding Goal

$100,000

Current Reservations

$5,000

Minimum Reservation

$5,000

Maximum Reservation

$50,000

Deal Stage

Bridge to Series A

Pre-money Valuation

$400,000

Open Date

02/03/2020

Closing Date

02/29/2020

Deal Exemption Type

3

Elevator Pitch

Geneaire ReBuilder™ is a Patented Natural Formulation designed to Promote Brain Longevity. 30 years of research and trials proves it also suppresses Alzheimer’s. You can help bring it to market.

KPIs

Cash Flow Positive
$Public+Patients Transaction Volume

Company Overview

Geneaire was founded a year and a half ago to make Geneaire ReBuilder™ available as rapidly as possible to patients diagnosed with Alzheimer’s disease. Technically a supplement, it is not currently marketed to “treat or prevent any disease” but is successfully sold to the public for its neural longevity benefits.

The formula of 13 natural ingredients is the result of over 30 years of scientific research carried out at the University of California at Irvine and by Genescient, Inc. Accredited and successful clinical trials led to its successful inclusion in the official treatment regimens for hundreds of Alzheimer’s patients over the last 4 years.

The research carried out at the University of California, Irvine and by Genescient, Inc. includes the development of the “Methuselah Flies” (fruit flies with lifespans over 3 times longer than normal flies). Cloud-based analytics and AI are used to perform detailed comparative genomic analysis, identification of specific genomic sites, and the determination of the combination of complex compounds that activate them. Long-term animal and human trials validate the results and are ongoing.

Geneaire has a founding principal of balancing genuine humanitarian goals by offering an affordable, natural solution to memory loss and brain degradation due to aging, and its associated diseases.

Geneaire ReBuilder ™ is the patented, exclusively licensed supplement available NOW (not some expensive drug available in 5+ years). We follow normal business practices and federal regulations, ensuring acceptable business risk with excellent potential return on investment.

  • Geneaire ReBuilder™ is the neurologist recommended formula based on animal AND human trials.
  • Geneaire was founded to provide this supplement to the general public. Geneaire is fully operational and has been selling Geneaire ReBuilder™ on Amazon for over a year.
  • Our target market (the brain supplement market) is estimated at over $1 Billion a year. Our product is differentiated by decades of science-based genomic research and years of clinical trials and live patient treatment.
  • Geneaire has a strong team of experienced executives and advisors. We are ready to grow our brand substantially with a long-term campaign.

62ca77e988f4508adae70aa19e0e5e53.jpg

Traction

  • In 2020, we are cash flow positive for over 12 months.

    January, 2020
  • In 2019, we completed a full year of sales and marketing.

    December, 2019
  • In 2018, we completed formation and initial manufacturing.

    December, 2018

Press Mentions

Key Customers & Partners

Amazon - Reseller (FBA) ISIS Nutritionals - Reseller

Testimonials

(From Amazon Review)
(From Amazon Review)
Amazon Review - Paul A. Gilster - Aug 2, 2019
"I have a family member whose Alzheimer's symptoms began 5 years ago. I began giving her ReBuilder over two years ago, having learned that it might be effective … I believe that ReBuilder has helped to slow the pace of the illness … and in many respects seem to have stabilized. As anyone knows who has dealt with Alzheimer's, little has emerged from the pharmaceutical laboratories … that has helped … As part of a program of medical supervision, ReBuilder should be looked at carefully as a choice …"

Previous Funding

  • $10,000 Equity
  • Raise Source: Investors
  • March 2019
  • $100,000 Equity
  • Raise Source: Investors
  • December 2018

Frequently Asked Questions

What does Geneaire do?

We provide Geneaire ReBuilder™ to help people live longer. Geneaire ReBuilder™ is the patented, exclusively licensed supplement with 13 natural ingredients. This is the result of over 30 years of research in the field of Genomics. Genomics is the study of the "programming" of living things. The brain is subject to damage due to stress, ageing, disease, lack of sleep, and air pollution. Geneaire ReBuilder™ has been tested successfully on animals AND in human clinical trials.

Where do we intend to be in 5 years?

Our goal is to reach sales in excess of $90 million a year within 5 years. The research has been done and paid for. Geneaire is fully operational. We now need funds to execute a long term campaign for publicity, marketing and brand recognition.

Why did we form Geneaire?

The researchers have dedicated a decade to a lifetime in the field of Genomics. They have literally written the book on the Methuselah Flies. The potential to increase healthy lifespan (healthspan) now exists. Geneaire ReBuilder™ promotes neurological function and resists brain degradation. Everyone involved is committed to longevity!

Why now?

In the last 5 years, human trials have been completed, new research has occurred, results have been published, and we have 5+ years of successful use of Geneaire ReBuilder™ by neurology patients. Over the last 2 years, failure after failure in trial after trial on neurological diseases of ageing by pharmaceutical companies has left huge deficit in options to preserve brain health. The decision was made to bring Geneaire ReBuilder™ to market as a safe supplement, allowing the general public access at an affordable price now, not at some uncertain date.

What is our competition?

The supplement industry is highly competitive, with a large number of products of questionable value. One seller of a memory product has reported sales of over $100 million a year. Market estimates for our kind of product exceed $1 billion a year (and growing). Therefore, there is excellent "market space" for us. Unlike other supplements, Geneaire ReBuilder™ is actually the result of science-based research and human trials with the goal of the researchers being longevity - not some short-term quick-buck item to sell. What we now have to do is "Get the Word Out"!

What are the risks?

Aside from the normal risks of any new or startup company, there is always the risk, however small, of some new solution to neural (brain) longevity being discovered. Despite the pharmaceutical companies pulling out of neurological research on the diseases of ageing after years of failed trials costing billions of dollars, there is always a chance of some "magic cure". Based on Genomics research, this is unlikely since we now know over 500 genomic sites affect longevity. (Drugs are single target, single site.) We are fully operational, the research over the last decade is done (and paid for), and we have over a year of sales. Our biggest risk of failure would be to not raise the funding to grow public awareness of Geneaire ReBuilder™. If public awareness is not increased, the buying public will continue to spend hundreds of millions of dollars a year on products we consider to be ineffective..

What is the funding to be used for?

The short answer is "To Get the Word Out!" Our intent is to use this funding cycle for a multi-dimensional publicity and marketing campaign. The basic approach is to use 50% of the funds raised to execute the campaign and 50% of the funds raised to support production of inventory to support sales growth. We are already cash-flow positive, with our basic operating expenses covered at our current sales volume level. We have normal and customary operating expenses, margins and distribution costs. We have researched our marketing campaign options with the resulting costs for the various options. Full details are available under non-disclosure to serious potential major investors. While there is a strong humanitarian aspect, both to continue serving the patients that completed the trial 4 years ago AND to make this available to the general public, we are committed to long-term sound business practices, processes and ethics. This means a slower "build" since we are not engaging in hype and unrealistic claims.

Risks & Disclosures

  • General risks of a small start-up/new company.
  • General risks due to a small management team.
  • Risk of a breakthrough product based on currently unknown research in the field of Genomics which surpasses what Geneaire ReBuilder™ has to offer.
  • Failure to gain market attention and retention even with substantial efforts made possible with this funding for marketing.
  • Some unforeseen issue with the product or its manufacturing that stops its availability for sale on a prompt basis.
  • Some unforeseen issue with Amazon.com which would require using an alternate form of selling. Some unforeseen issue with any potential distributors we might contract with.

Documents

Confidential

Loading...